BioSpace News Archive

The National Advertising Division (NAD) of BBB National Programs determined that certain claims for Pendulum Glucose Control, manufactured by Pendulum Therapeutics, Inc. to help Type 2 diabetes dietary management, were supported by competent and reliable scientific evidence:

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual 33rd Annual Roth Conference, being held March 15-17, 2021.

Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces a licensing and collaboration agreement with Munich-based SIRS Theraputics and Vienna-based F4 Pharma to support the development of FX-06, a synthetic peptide that has a broad spectrum of potential indications.

Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity and infectious disease, today announced pre-published data revealing new insights into T cell recognition of SARS-CoV-2

Altasciences is pleased to support ReAlta Life Sciences by conducting a Phase I trial to evaluate RLS-0071 for treatment of Acute Lung Injury (ALI) as a result of viral infections, such as COVID-19, respiratory syncytial virus (RSV), and influenza.

InnerScope Hearing Technologies Inc. (OTC: INND) (“InnerScope”) announced today it has completed and updated the FDA Medical Device Registration for Class II Hearing Aid, Air Conduction with Wireless Technology (“FDA Medical Device Registration”).

Economic activity in the services sector grew in February for the ninth month in a row, say the nation’s purchasing and supply executives in the latest Services ISM® Report On Business®.

Geneoscopy Inc., a life sciences company that develops diagnostic tests for gastrointestinal health, today announced the appointment of Vince Wong as Chief Commercial Officer.

NEXGEL, Inc., an innovative company developing ultra-gentle, high-water content E-beam hydrogels with a focus on the consumer over the counter, Rx, medical device and cosmetic markets, announced that it has engaged its first independent sales representatives to expand its customer base globally.

Vaxalto Biotherapeutics, Inc. (www.vaxalto.com), a pre-clinical stage biotechnology company focused on developing and commercializing novel engineered immunotherapeutic oncolytic viruses, and Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, have partnered to develop novel cancer immunotherapies.